IFI-A · Catechin Profile Optimization

Specimen SS-F-AST-348 // ASTRINGENCY · IFI-A

Catechin Profile Optimization IV-BL-B

Camellia sinensis

Tea

Tier IVCatechin Profile Optimization

Target Trait

3.43×

fold-change

EGCG:ECG:EC catechin molar ratio index

Technical Specifications

SKU

SS-F-AST-348

Genomic Edits

8

GC Content

47.0%

Construct Length

4,280 bp

Promoter System

CaMV 35S / Ubiquitin

Expression System

Biolistic transformation

Host Strain

Particle Gun

Receptor Target

Polyphenol-astringency axis

IFI Score

343

Pathway Edits

  • ANR differential expression (anthocyanidin reductase) for epicatechin flux control
  • LAR allelic balancing (leucoanthocyanidin reductase) for catechin:epicatechin ratio
  • F3-5H overexpression (flavonoid 3',5'-hydroxylase) for gallated catechin precursor enrichment
  • DFR allelic selection for 3',4'- vs 3',4',5'-dihydroxyl substrate preference
  • FLS suppression (flavonol synthase) to redirect dihydroflavonol flux toward catechins
  • Biolistic tungsten-particle coating for leaf/seed explant delivery
  • Enhanced flux via 5'UTR synthetic leader sequence optimization

Key Interventions

EGCG:ECG:EC catechin ratio precision control via ANR/LAR differential tuningF3-5H hydroxylation pattern optimization for gallated versus non-gallated catechin distributionDFR allelic switching for substrate specificity toward epicatechin pathwayHigh-pressure helium particle acceleration at 1100 psiVariant B enhanced: iterative codon optimization for host-matched expression

IFI Subscale Profile

IFI Profile

IFI-S
—
IFI-U
—
IFI-B
—
IFI-K
—
IFI-C
—
IFI-P
—
IFI-A
343
IFI-F
—

Use Case

Industrial EGCG ingredient extraction, premium specialty tea formulation, pharmaceutical catechin precursor production. Enhanced variant for premium or research-grade applications requiring peak astringency fidelity.

License

$4049 · Tier IV License

Includes full construct sequence, CRISPR guide designs, pathway edit specifications, flux balance analysis, and IFI validation data.

Already purchased?